- Home
- PMVP vs ADVM Comparison
PMVP vs ADVM Comparison
Compare PMVP & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ADVM
- Stock Information
- Founded
- PMVP 2013
- ADVM 2006
- Country
- PMVP United States
- ADVM United States
- Employees
- PMVP N/A
- ADVM N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- ADVM Health Care
- Exchange
- PMVP Nasdaq
- ADVM Nasdaq
- Market Cap
- PMVP 71.9M
- ADVM 59.5M
- IPO Year
- PMVP 2020
- ADVM 2014
- Fundamental
- Price
- PMVP $0.88
- ADVM $2.81
- Analyst Decision
- PMVP Strong Buy
- ADVM Strong Buy
- Analyst Count
- PMVP 2
- ADVM 5
- Target Price
- PMVP $5.50
- ADVM $26.60
- AVG Volume (30 Days)
- PMVP 167.4K
- ADVM 517.4K
- Earning Date
- PMVP 05-09-2025
- ADVM 05-20-2025
- Dividend Yield
- PMVP N/A
- ADVM N/A
- EPS Growth
- PMVP N/A
- ADVM N/A
- EPS
- PMVP N/A
- ADVM N/A
- Revenue
- PMVP N/A
- ADVM $1,000,000.00
- Revenue This Year
- PMVP N/A
- ADVM N/A
- Revenue Next Year
- PMVP N/A
- ADVM $42.58
- P/E Ratio
- PMVP N/A
- ADVM N/A
- Revenue Growth
- PMVP N/A
- ADVM N/A
- 52 Week Low
- PMVP $0.82
- ADVM $2.64
- 52 Week High
- PMVP $2.26
- ADVM $10.84
- Technical
- Relative Strength Index (RSI)
- PMVP 33.52
- ADVM 38.23
- Support Level
- PMVP $0.85
- ADVM $2.64
- Resistance Level
- PMVP $1.04
- ADVM $3.64
- Average True Range (ATR)
- PMVP 0.06
- ADVM 0.32
- MACD
- PMVP -0.01
- ADVM 0.04
- Stochastic Oscillator
- PMVP 11.28
- ADVM 17.00
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.